Amgen (NASDAQ:AMGN) dropped -1.45% or -2.21 points to trade at $150.1 per share. As per the latest trading data available, the net money flow stood at $81.18 million as the shares received $162.72 million in upticks and gave away $81.54 million in downticks. The final up/down ratio was at 2. On a weekly basis, the stock has seen a change of -3.03%.During the course of the session, the shares witnessed a block trade with an up/down ratio of 5.71. $107.87 million was the inflow in upticks and $18.88 million was the outflow in downticks. For the block trade, the net money flow was $89 million.
Amgen Inc. has lost 3.33% in the last five trading days and dropped 0.8% in the last 4 weeks. Amgen Inc. is up 3.5% in the last 3-month period. Year-to-Date the stock performance stands at -6.58%.
Currently the company Insiders own 0.2% of Amgen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -25.24% . Institutional Investors own 83.17% of Amgen shares. During last six month period, the net percent change held by insiders has seen a change of -25.24%. . On the companys insider trading activities, The Securities and Exchange Commission has divulged that Balachandran Madhavan, officer (EVP, Operations) of Amgen Inc, had unloaded 30,000 shares at an average price of $154.12 in a transaction dated on May 4, 2016. The total value of the transaction was worth $4,623,600.
Amgen (NASDAQ:AMGN) witnessed a decline in the market cap on Friday as its shares dropped 1.76% or 2.68 points. After the session commenced at $152.61, the stock reached the higher end at $152.76 while it hit a low of $149.55. With the volume soaring to 4,682,336 shares, the last trade was called at $149.62. The company has a 52-week high of $181.81. The company has a market cap of $112,397 million and there are 751,217,080 shares in outstanding. The 52-week low of the share price is $130.09.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.